Impact of Age and Colony-Stimulating Factor Use on Hospital Length of Stay for Febrile Neutropenia in CHOP-Treated Non-Hodgkin's Lymphoma

Cancer Control - Tập 9 Số 3 - Trang 203-211 - 2002
Elizabeth A. Chrischilles1, David J. Delgado2, Bradley S. Stolshek2, Grant Lawless2, Moshe Fridman3, William B. Carter2
1University of Iowa, Iowa City, Iowa
2Amgen, Inc., Thousand Oaks, California
3AMF Consulting, Inc., Los Angeles, California

Tóm tắt

Background

In intermediate-grade non-Hodgkin's lymphoma (NHL) patients, full-dose CHOP improves survival but increases myelosuppression, causing febrile neutropenia hospitalization (FNH) in 28% of patients 65 years of age or greater. Several risk factors for FNH are known, but their relationship to length of stay (LOS), an indicator of the total burden of FNH, is unclear.

Methods

We conducted a study to identify factors associated with the incidence, recurrence, and duration of hospitalizations for FN and to describe the frequency of administration of colony-stimulating factor (CSF) as primary and secondary prophylaxis and its association with repeated hospitalization episodes.

Results

Compared with patients who did not experience hospitalizations for FN, those who did were significantly older, had more comorbid conditions, were planned for standard dose intensity, and received CSF less often during the first 5 days of cycle 1 (early CSF). Overall, 73% of these hospitalizations occurred within the first 2 cycles of chemotherapy, with 56% occurring within the first cycle. Patients age ≥65 years accounted for 66% of cycle 1 FNH. Patients receiving early CSF were less likely to experience repeated hospitalizations (0% vs 12%; P.05). Multiple regression analysis of those hospitalized found a 3.9-day longer LOS for patients age ≥65 years and a 5.13-day longer LOS for those not receiving early CSF.

Conclusions

Older NHL patients have a higher risk of hospitalization for FN and longer LOS. The majority of hospitalization days occur in the first 2 cycles of chemotherapy. Early CSF use is associated with decreased risk of repeated hospitalizations and shorter total LOS. Secondary CSF use is also associated with reduced risk of repeated FNH.

Từ khóa


Tài liệu tham khảo

10.1093/jnci/91.8.675

10.3322/canjclin.52.1.23

10.1002/(SICI)1097-0142(19971215)80:12<2311::AID-CNCR13>3.0.CO;2-X

10.1056/NEJM199304083281404

Coltman C.A., 1986, Update on Treatment for Diffuse Large Cell Lymphoma., 71

10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I

Tirelli U., 1998, J Clin Oncol., 16, 27, 10.1200/JCO.1998.16.1.27

10.1200/JCO.1986.4.3.295

Epelbaum R., 1988, Isr J Med Sci., 24, 533

10.1200/JCO.1990.8.6.963

10.1093/oxfordjournals.annonc.a058619

Gaynor E.R., 1994, Proc Annu Meet Am Soc Clin Oncol., 13, 1250

10.1111/j.1532-5415.1984.tb02020.x

10.1200/JCO.1998.16.6.2065

10.3109/10428190009053540

10.1056/NEJM199107183250305

10.1056/NEJM199009273231304

10.1056/NEJM198806023182202

10.1038/bjc.1987.295

Jacobson J.O., 1998, Proc Annu Meet Am Soc Clin Oncol., 17, 41

Zinzani P.L., 1997, Blood., 89, 3974

Zinzani P.L., 1999, Blood., 94, 33, 10.1182/blood.V94.10.3289.422k32_3289_3293

Bjorkholm M., 1999, Blood., 94, 2665

10.3816/CLM.2001.n.011

10.1016/0021-9681(87)90171-8

10.1016/0895-4356(92)90133-8

10.1016/0895-4356(93)90103-8

Carbone P.P., 1971, Cancer Res., 31, 1860

10.1002/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2

10.1200/JCO.1984.2.11.1281

Balducci L., 2001, Cancer Control., 8, 1, 10.1177/107327480100800214

10.2165/00003495-199753060-00005

10.2165/00002512-199914060-00005

10.1111/j.1532-5415.1991.tb05927.x

Blayney D.W., 1992, Proc Annu Meet Am Soc Clin Oncol., 11, 1088

10.1200/JCO.1994.12.11.2471

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidenced-based clinical practice guidelines., 1996, J Clin Oncol., 14, 1957, 10.1200/JCO.1996.14.6.1957

10.1200/JCO.2000.18.20.3558

10.1097/00062752-200105000-00008

10.1016/S0959-8049(00)00169-6